Novel vectors for in vivo gene delivery to vascular tissue.
Although some success has been achieved with gene delivery in animal models of vascular disorders, the results from some clinical trials have been less promising, possibly due, in part, to the use of suboptimal vectors for in vivo gene transfer. Non-viral vectors have a very low transfection efficiency so are largely unsuitable for most in vivo applications, and the relatively broad tropism of many of the commonly used viral vectors can limit efficient gene delivery specifically to target vascular tissues. However, characterisation of novel virus serotypes and advances in techniques that enable vectors to be targeted to the required tissue have led to progress in the development of novel vectors that could be utilised for gene delivery for vascular disorders.
White
Kathryn
K
University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, UK.
Nicklin
Stuart A
SA
Baker
Andrew H
AH
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002318:Cardiovascular Diseases / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D002467:Cell Nucleus / Q000378:metabolism; D004247:DNA / Q000378:metabolism*; D000229:Dependovirus / Q000235:genetics; D003952:Diagnostic Imaging; D017988:Gammaretrovirus / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D014161:Transduction, Genetic; D014162:Transfection; D019076:Transgenes
D004247:DNA